Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer. uri icon

Overview

publication date

  • October 26, 2016

Research

keywords

  • Adenocarcinoma
  • Antineoplastic Agents
  • Drug-Related Side Effects and Adverse Reactions
  • Erlotinib Hydrochloride
  • Lung Diseases, Interstitial
  • Lung Neoplasms
  • Quinazolines

Identity

PubMed Central ID

  • PMC5490243

Scopus Document Identifier

  • 85006827077

Digital Object Identifier (DOI)

  • 10.1016/j.cllc.2016.10.001

PubMed ID

  • 27863924

Additional Document Info

volume

  • 18

issue

  • 1